Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials

Annals of Internal Medicine

Volumn 127, Issue 5, 1997, Pages 337-345

  Giatras, Ioannis ^a   Lau, Joseph ^a   Levey, Andrew S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NIFEDIPINE; PLACEBO;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 0030818790     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-5-199709010-00001     Document Type: Review

References (33)

1. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271:275-9.
2. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99:497-503.
3. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ. 1992;304:339-43.
4. Lewis JE, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-62.
5. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-38.
6. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996; 334:939-45.
7. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-8.
8. Zucchelli P, Zuccala A, Gaggi R. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrol Dial Transplant. 1995;10:46-51.
9. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens. 1992;5:423-30.
10. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, et al. Randomized controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. BMJ. 1994;309:833-7.
11. Bannister KM, Weaver A, Clarkson AR, Woodroffe AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol. 1995;111:184-93.
12. Becker GJ, Whitworth JA, Ihle BU, Shahinfar S, Kincaid-Smith PS. Prevention of progression in non-diabetic chronic renal failure. Kidney Int Suppl. 1994;45:S167-70.
13. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 1996; 27:489-95.
14. Himmelmann A, Hansson L, Hannson BG, Hedstrand H, Skogstrom K, Ohrvik J, et al. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension. Blood Press. 1995;4:85-90.
15. Bianchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nephrol. 1991;11:131-7.
16. Remuzzi G, Tognoni G, Ruggenenti P, Perna A. A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN). Journal of Nephrology. 1991;3:193-202.
17. Okamura M, Kanayama Y, Negoro N, Inoue T, Takeda T. Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. Contrib Nephrol. 1991;90:161-5.
18. Sacks HS, Berrier J, Restman D, Ancona-Berk VA, Chalmers T. Meta-analysis of randomized controlled trials. N Engl J Med. 1987;316:450-5.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
20. Berlin JA, Antman EM. Advantages and limitations of metaanalytic regressions of clinical trials data. Online J Curr Clin Trials. 1994; Jun 4: Doc No134.
21. U.S. Renal Data System. USRDS 1995 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995:B1, 70, 154.
22. Levey AS. Measurment of renal function in chronic renal disease [Clinical Conference]. Kidney Int. 1990;38:167-84.
23. Levey AS, Bosch JP, Coggins CH, Greene T, Mitch WE, Schluchter MD, et al. Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:556-66.
24. Levey AS, Beck GJ, Bosch JP, Caggiula AW, Greene T, Hunsicker LG, et al. Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2097-109.
25. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-84.
26. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-62.
27. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993-2000.
28. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, et al. Predictors of progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908-19.
29. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-42.
30. Keane FW, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med. 1989;111:503-16.
31. Brunner HR. ACE inhibitors in renal disease [Clinical Conference]. Kidney Int. 1992;42:463-79.
32. Hunsicker LG, Levey AS. Progression of chronic renal disease. Mechanisms, risk factors, and testing of interventions. In: Jacobson HR, Striker GE, Klahr S, eds. The Principles and Practice of Nephrology. 2d ed. St. Louis: Mosby-Year Book; 1995:622-31.
33. Ichikawa I. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney Int. 1996;50:684-92.